Logo for XORTX Therapeutics Inc.

XORTX Therapeutics Inc.

Issued & Outstanding9,728,687
Reserved for Issuance2,362,168
CSE Index


XORTX Therapeutics Inc.

Listing date
September 30, 2015

XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients.  Additional information on XORTX Therapeutics is available at www.xortx.com.